Safe Harbor Wealth Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Safe Harbor Wealth Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	$213K	Buy	+457	New	+$197K	0.21%	94

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Safe Harbor Wealth Advisors's VRTX Position: Q4 2025 in Review

Safe Harbor Wealth Advisors opened a new position in Vertex Pharmaceuticals (VRTX) in Q4 2025: 457 shares worth $213K. The stake represents 0.21% of the portfolio and ranks #94 among its holdings.

1,670 funds tracked by Wall St. Rank hold VRTX as of Q4 2025.

Safe Harbor Wealth Advisors held 457 shares of Vertex Pharmaceuticals worth $213K as of Q4 2025.
Vertex Pharmaceuticals was a new Safe Harbor Wealth Advisors position in Q4 2025.
Vertex Pharmaceuticals made up 0.21% of Safe Harbor Wealth Advisors's portfolio in Q4 2025, its #94 holding.
1,670 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2025.

Based on Safe Harbor Wealth Advisors's 13F filing for Q4 2025, filed 13 Feb 2026.